Beam Therapeutics 

Beam Therapeutics 

Yahoo Finance • 4 days ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 5 days ago

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its genetic source rather than primarily managing downstream symptoms. Unlike conventional therapies that may require chro... Full story

Yahoo Finance • 25 days ago

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in... Full story

Yahoo Finance • 26 days ago

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. S... Full story

Yahoo Finance • last month

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strok... Full story

Yahoo Finance • last month

ARK Invest snaps up $16.7M in SPCX shares, trims Deere exposure

[Man looking at currency trading app on his smart phone from his home office] Alistair Berg * Cathie Wood’s ARK Invest doubled down on its aerospace bet on Wednesday, snapping up 122,807 shares of Space Exploration Technologies Corp (SP... Full story

Yahoo Finance • last month

Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a fa... Full story

Yahoo Finance • last month

Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therape... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $22.8 million of surging tech stock

Cathie Wood, CEO of Ark Investment Management, is known for investing in high-growth tech companies. She'll even add to positions amid strong gains, and that's what she just did, adding shares of a megacap stock that has surged 14.8% over... Full story

Yahoo Finance • 2 months ago

Prime Medicine gains after winning arbitration with Beam Therapeutics

[Genetic engineering] Andy/iStock via Getty Images Prime Medicine (PRME [https://seekingalpha.com/symbol/PRME]) added ~8% in the premarket on Wednesday after an arbitration tribunal sided with the gene editing company in connection with a... Full story

Yahoo Finance • 2 months ago

Cathie Wood buys $11.5 million of battered tech stock

Cathie Wood, chief of Ark Investment Management, likes to double down on her favorite tech stocks when the prices are falling, hoping for a bargain. That's what Wood just did, adding shares of Coinbase after weeks of tumbling. In 2025, W... Full story

Yahoo Finance • 3 months ago

Draft FDA guidance could be a boon for gene therapy developers

[Genetic Medicine And DNA Therapy] narvo vexar * The US FDA has issued draft guidance intended to accelerate the development of gene and cell therapies. * The agency hopes the document will enhance the R&D process for the treatments "... Full story

Yahoo Finance • 3 months ago

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?

Key Points CRISPR Therapeutics has an approved product and several gene editing medicines in development. Beam Therapeutics is exploring ways to develop safer gene-editing therapies. One of these stocks is a lot less risky than the other.... Full story

Yahoo Finance • 3 months ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story

Yahoo Finance • 4 months ago

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam logo CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated... Full story

Yahoo Finance • 4 months ago

Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates

A week ago, Beam Therapeutics Inc. (NASDAQ:BEAM) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. Revenues of US$32m beat estimates by a substantial 160% margin. Unfortunately, Beam The... Full story

Yahoo Finance • 4 months ago

Cathie Wood buys $12.9 million of tumbling tech stock

Cathie Wood, chief of Ark Investment Management, is known for making bold bets on fast-moving tech stocks. Sometimes her trades move just as quickly as the stocks themselves. In the week that began on May 3, Wood sold millions of dollars... Full story

Yahoo Finance • 4 months ago

Is Beam Therapeutics Inc. (BEAM) A Good Stock To Buy Now?

Is BEAM a good stock to buy? We came across a bullish thesis on Beam Therapeutics Inc. on r/ValueInvesting by Significant-Pair-275. In this article, we will summarize the bulls’ thesis on BEAM. Beam Therapeutics Inc.'s share was trading at... Full story

Yahoo Finance • 4 months ago

Cathie Wood sells $75M of surging semiconductor stock

Cathie Wood, head of Ark Investment Management, often takes advantage of market swings. That’s what she just did, selling shares of a semiconductor stock after it jumped 25% in a week. Last year, Wood’s flagship Ark Innovation ETF (ARKK)... Full story

Yahoo Finance • 4 months ago

Cathie Wood buys $2.5 million of tumbling megacap stock

Cathie Wood, head of Ark Investment Management, was relatively quiet this week, even as the S&P 500 rallied about 4.5% over the past five days. Wood made no trades on Tuesday, April 14, and Wednesday, April 15, and sold some shares of two... Full story